ABSTRACT
Here we describe a relatively quick, simple, economical and accurate laboratory developed test (LDT) for detection of SARS-CoV-2 in heated and diluted saliva samples without RNA extraction. Our protocol is a variation of the University of Illinois Urbana-Champaign SHIELD LDT. Differences include chilling of the samples during dilution and using a reduced volume for the qRT-PCR reactions. The level of detection for our LDT is 3125 copies/ml, which compares favorably with other saliva-based tests. Initial validation studies with a limited number of patient samples have demonstrated excellent agreement between results using our LDT and those obtained from external laboratories. The cost of consumables for our test is under $8 and a throughput of 1000 tests/day can be achieved with 3-4 personnel.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received to support this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We partnered with the Veitch Student Health Services High Complexity Laboratory at the University of California, Riverside (UCR), to establish a CLIA Extension Laboratory at a non-contiguous location on campus. We received approval of our application to establish a temporary CLIA Extension Laboratory from the Centers for Medicare & Medicaid Services (CMS) and the California Department of Public Health (CDPH) (Robert J. Thomas, Branch Chief, Laboratory Field Services) on June 10, 2020 (State ID# CLF-00002131-T1). Our test has been validated in compliance with CMS CLIA regulations, but has not been submitted to the Food and Drug Administration (FDA) for Emergency Use Authorization. Because we are not using the saliva samples for research, and are an extension of the clinical laboratory in Veitch Student Health Services, the UCR Institutional Biosafety Committee in the UCR Office of Research and Economic Development did not require a Biological Use Authorization or IRB approval for research with human subjects (Vice Chancellor Rodolfo Torres granted the waiver). Our Standard Operating Procedures (SOPs) for our testing protocol and our requirements for Personal Protective Equipment (PPE) were approved by the Veitch Student Health Services High Complexity Laboratory Director Kenneth Han and Assistant Biosafety Officer & High Containment Lab Director Tran Phan at UCR Environmental Health and Safety. All laboratory personnel were trained according to the approved SOPs and registered with CDPH.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is available upon request.
